Lactococcus lactis-based vaccines from laboratory bench to human use: An overview

Vaccine

Volumn 30, Issue 4, 2012, Pages 685-690

  Bahey El Din, Mohammed ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Biological containment; Delivery system; GEM; Lactococcus lactis; Mimopath; Mucosal vaccine

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL VACCINE; LACTOBACILLUS VACCINE; LACTOCOCCUS LACTIS VACCINE; MITOMYCIN C; PNEUMOCOCCAL ANTIGEN PPPA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; IMMUNOMODULATION; LACTOCOCCUS LACTIS; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; VACCINATION;

DRUG CARRIERS; GENETIC VECTORS; HUMANS; LACTOCOCCUS LACTIS; TECHNOLOGY, PHARMACEUTICAL; VACCINES;

EID: 84855349064     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.098     Document Type: Review

References (70)

1. Wells J.M., Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008, 6(5):349-362.
2. Medina M., Villena J., Salva S., Vintini E., Langella P., Alvarez S. Nasal administration of Lactococcus lactis improves local and systemic immune responses against Streptococcus pneumoniae. Microbiol Immunol 2008, 52(8):399-409.
3. Villena J., Medina M., Vintini E., Alvarez S. Stimulation of respiratory immunity by oral administration of Lactococcus lactis. Can J Microbiol 2008, 54(8):630-638.
4. Moorthy G., Ramasamy R. Mucosal immunisation of mice with malaria protein on lactic acid bacterial cell walls. Vaccine 2007, 25(18):3636-3645.
5. Robinson K., Chamberlain L.M., Schofield K.M., Wells J.M., Le Page R.W. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol 1997, 15(7):653-657.
6. Sevil Domenech V.E., Panthel K., Meinel K.M., Winter S.E., Russmann H. Pre-existing anti-Salmonella vector immunity prevents the development of protective antigen-specific CD8 T-cell frequencies against murine listeriosis. Microbes Infect 2007, 9(12-13):1447-1453.
7. Mills S., McAuliffe O.E., Coffey A., Fitzgerald G.F., Ross R.P. Plasmids of lactococci-genetic accessories or genetic necessities?. FEMS Microbiol Rev 2006, 30(2):243-273.
8. Law J., Buist G., Haandrikman A., Kok J., Venema G., Leenhouts K. A system to generate chromosomal mutations in Lactococcus lactis which allows fast analysis of targeted genes. J Bacteriol 1995, 177(24):7011-7018.
9. Cotter P.D., Hill C., Ross R.P. A food-grade approach for functional analysis and modification of native plasmids in Lactococcus lactis. Appl Environ Microbiol 2003, 69(1):702-706.
10. Jiang S., Rasmussen R.A., Nolan K.M., Frankel F.R., Lieberman J., McClure H.M., et al. Live attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys. Vaccine 2007, 25(42):7470-7479.
11. Medina E., Guzman C.A. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 2001, 19(13-14):1573-1580.
12. Russmann H., Igwe E.I., Sauer J., Hardt W.D., Bubert A., Geginat G. Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins. J Immunol 2001, 167(1):357-365.
13. Sirard J.C., Fayolle C., de Chastellier C., Mock M., Leclerc C., Berche P. Intracytoplasmic delivery of listeriolysin O by a vaccinal strain of Bacillus anthracis induces CD8-mediated protection against Listeria monocytogenes. J Immunol 1997, 159(9):4435-4443.
14. Bahey-El-Din M., Gahan C.G., Griffin B.T. Lactococcus lactis as a cell factory for delivery of therapeutic proteins. Curr Gene Ther 2010, 10(1):34-45.
15. Bahey-El-Din M., Casey P.G., Griffin B.T., Gahan C.G. Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8(+) T cells against Listeria monocytogenes in the murine infection model. Vaccine 2008, 26(41):5304-5314.
16. Vazquez-Boland J.A., Kuhn M., Berche P., Chakraborty T., Dominguez-Bernal G., Goebel W., et al. Listeria pathogenesis and molecular virulence determinants. Clin Microbiol Rev 2001, 14(3):584-640.
17. Pamer E.G. Immune responses to Listeria monocytogenes. Nat Rev Immunol 2004, 4(10):812-823.
18. Bermudez-Humaran L.G., Langella P., Cortes-Perez N.G., Gruss A., Tamez-Guerra R.S., Oliveira S.C., et al. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun 2003, 71(4):1887-1896.
19. Robinson K., Chamberlain L.M., Lopez M.C., Rush C.M., Marcotte H., Le Page R.W., et al. Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C. Infect Immun 2004, 72(5):2753-2761.
20. Bermudez-Humaran L.G., Cortes-Perez N.G., Le Loir Y., Alcocer-Gonzalez J.M., Tamez-Guerra R.S., de Oca-Luna R.M., et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 2004, 53(Pt 5):427-433.
21. Perez C.A., Eichwald C., Burrone O., Mendoza D. Rotavirus vp7 antigen produced by Lactococcus lactis induces neutralizing antibodies in mice. J Appl Microbiol 2005, 99(5):1158-1164.
22. Miyoshi A., Bermudez-Humaran L.G., Ribeiro L.A., Le Loir Y., Oliveira S.C., Langella P., et al. Heterologous expression of Brucella abortus GroEL heat-shock protein in Lactococcus lactis. Microb Cell Fact 2006, 5:14.
23. Le Loir Y., Azevedo V., Oliveira S.C., Freitas D.A., Miyoshi A., Bermudez-Humaran L.G., et al. Protein secretion in Lactococcus lactis: an efficient way to increase the overall heterologous protein production. Microb Cell Fact 2005, 4(1):2.
24. Bahey-El-Din M., Casey P.G., Griffin B.T., Gahan C.G. Expression of two Listeria monocytogenes antigens (P60 and LLO) in Lactococcus lactis and examination for use as live vaccine vectors. J Med Microbiol 2010, 59(Pt 8):904-912.
25. Buccato S., Maione D., Rinaudo C.D., Volpini G., Taddei A.R., Rosini R., et al. Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease. J Infect Dis 2006, 194(3):331-340.
26. Daniel C., Sebbane F., Poiret S., Goudercourt D., Dewulf J., Mullet C., et al. Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV. Vaccine 2009, 27(8):1141-1144.
27. Enouf V., Langella P., Commissaire J., Cohen J., Corthier G. Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic. Appl Environ Microbiol 2001, 67(4):1423-1428.
28. Medina M., Villena J., Vintini E., Hebert E.M., Raya R., Alvarez S. Nasal immunization with Lactococcus lactis expressing the pneumococcal protective protein A induces protective immunity in mice. Infect Immun 2008, 76(6):2696-2705.
29. Lee M.H., Roussel Y., Wilks M., Tabaqchali S. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine 2001, 19(28-29):3927-3935.
30. Drouault S., Corthier G., Ehrlich S.D., Renault P. Survival, physiology, and lysis of Lactococcus lactis in the digestive tract. Appl Environ Microbiol 1999, 65(11):4881-4886.
31. Kimoto H., Nomura M., Kobayashi M., Mizumachi K., Okamoto T. Survival of lactococci during passage through mouse digestive tract. Can J Microbiol 2003, 49(11):707-711.
32. Villena J., Medina M., Raya R., Alvarez S. Oral immunization with recombinant Lactococcus lactis confers protection against respiratory pneumococcal infection. Can J Microbiol 2008, 54(10):845-853.
33. Hanniffy S.B., Carter A.T., Hitchin E., Wells J.M. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis 2007, 195(2):185-193.
34. Pei H., Liu J., Cheng Y., Sun C., Wang C., Lu Y., et al. Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination. Appl Microbiol Biotechnol 2005, 68(2):220-227.
35. Sim A.C., Lin W., Tan G.K., Sim M.S., Chow V.T., Alonso S. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen. Vaccine 2008, 26(9):1145-1154.
36. Chamberlain L., Wells J., Robinson K., Schofield K., Page R.L. Mucosal immunization with recombinant Lactococcus lactis. Gram-positive bacteria as vaccine vehicles for mucosal immunisation 1997, 83-106. Landes Bioscience, Austin, TX. G. Pozzi, J. Wells (Eds.).
37. van der Vossen J.M., van der Lelie D., Venema G. Isolation and characterization of Streptococcus cremoris Wg2-specific promoters. Appl Environ Microbiol 1987, 53(10):2452-2457.
38. de Vos W.M., Vaughan E.E. Genetics of lactose utilization in lactic acid bacteria. FEMS Microbiol Rev 1994, 15(2-3):217-237.
39. O'Sullivan D.J., Walker S.A., West S.G., Klaenhammer T.R. Development of an expression strategy using a lytic phage to trigger explosive plasmid amplification and gene expression. Biotechnology (NY) 1996, 14(1):82-87.
40. van Rooijen R.J., Gasson M.J., de Vos W.M. Characterization of the Lactococcus lactis lactose operon promoter: contribution of flanking sequences and LacR repressor to promoter activity. J Bacteriol 1992, 174(7):2273-2280.
41. Wells J.M., Wilson P.W., Norton P.M., Gasson M.J., Le Page R.W. Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol Microbiol 1993, 8(6):1155-1162.
42. Mierau I., Kleerebezem M. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 2005, 68(6):705-717.
43. Nouaille S., Ribeiro L.A., Miyoshi A., Pontes D., Le Loir Y., Oliveira S.C., et al. Heterologous protein production and delivery systems for Lactococcus lactis. Genet Mol Res 2003, 2(1):102-111.
44. Xin K.Q., Hoshino Y., Toda Y., Igimi S., Kojima Y., Jounai N., et al. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood 2003, 102(1):223-228.
45. Steidler L., Robinson K., Chamberlain L., Schofield K.M., Remaut E., Le Page R.W., et al. Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect Immun 1998, 66(7):3183-3189.
46. Bermudez-Humaran L.G., Cortes-Perez N.G., Lefevre F., Guimaraes V., Rabot S., Alcocer-Gonzalez J.M., et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005, 175(11):7297-7302.
47. Vintini E., Villena J., Alvarez S., Medina M. Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis-PppA induces effective protection against pneumococcal infection in young mice. Clin Exp Immunol 2010, 159(3):351-362.
48. van Roosmalen M.L., Kanninga R., El Khattabi M., Neef J., Audouy S., Bosma T., et al. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods 2006, 38(2):144-149.
49. Bosma T., Kanninga R., Neef J., Audouy S.A., van Roosmalen M.L., Steen A., et al. Novel surface display system for proteins on non-genetically modified gram-positive bacteria. Appl Environ Microbiol 2006, 72(1):880-889.
50. Audouy S.A., van Selm S., van Roosmalen M.L., Post E., Kanninga R., Neef J., et al. Development of lactococcal GEM-based pneumococcal vaccines. Vaccine 2007, 25(13):2497-2506.
51. Audouy S.A., van Roosmalen M.L., Neef J., Kanninga R., Post E., van Deemter M., et al. Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization. Vaccine 2006, 24(26):5434-5441.
52. Ramasamy R., Yasawardena S., Zomer A., Venema G., Kok J., Leenhouts K. Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations. Vaccine 2006, 24(18):3900-3908.
53. Ramirez K., Ditamo Y., Rodriguez L., Picking W.L., van Roosmalen M.L., Leenhouts K., et al. Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Mucosal Immunol 2010, 3(2):159-171.
54. Saluja V., Amorij J.P., van Roosmalen M.L., Leenhouts K., Huckriede A., Hinrichs W.L., et al. Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. AAPS J 2010, 12(2):109-116.
55. Saluja V., Visser M.R., Ter Veer W., van Roosmalen M.L., Leenhouts K., Hinrichs W.L., et al. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles. Vaccine 2010, 28(50):7963-7969.
56. Steidler L., Rottiers P., Coulie B. Actobiotics as a novel method for cytokine delivery. Ann N Y Acad Sci 2009, 1182:135-145.
57. Steidler L., Neirynck S., Huyghebaert N., Snoeck V., Vermeire A., Goddeeris B., et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003, 21(7):785-789.
58. Jeong D.W., Lee J.H., Kim K.H., Lee H.J. A food-grade expression/secretion vector for Lactococcus lactis that uses an alpha-galactosidase gene as a selection marker. Food Microbiol 2006, 23(5):468-475.
59. Bahey-El-Din M., Casey P.G., Griffin B.T., Gahan C.G.M. Efficacy of a Lactococcus lactis ΔpyrG vaccine delivery platform expressing chromosomally integrated hly from Listeria monocytogenes. Bioengineered Bugs 2010, 1(1):66-74.
60. Kaplan D.L., Mello C., Sano T., Cantor C., Smith C. Streptavidin-based containment systems for genetically engineered microorganisms. Biomol Eng 1999, 16(1-4):135-140.
61. Knudsen S., Saadbye P., Hansen L.H., Collier A., Jacobsen B.L., Schlundt J., et al. Development and testing of improved suicide functions for biological containment of bacteria. Appl Environ Microbiol 1995, 61(3):985-991.
62. Torres B., Jaenecke S., Timmis K.N., Garcia J.L., Diaz E. A gene containment strategy based on a restriction-modification system. Environ Microbiol 2000, 2(5):555-563.
63. Sorensen K.I., Larsen R., Kibenich A., Junge M.P., Johansen E. A food-grade cloning system for industrial strains of Lactococcus lactis. Appl Environ Microbiol 2000, 66(4):1253-1258.
64. Ahmad S.I., Kirk S.H., Eisenstark A. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu Rev Microbiol 1998, 52:591-625.
65. Braat H., Rottiers P., Hommes D.W., Huyghebaert N., Remaut E., Remon J.P., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006, 4(6):754-759.
66. Buckland B.C. The process development challenge for a new vaccine. Nat Med 2005, 11(4 Suppl.):S16-S19.
67. Huyghebaert N., Vermeire A., Neirynck S., Steidler L., Remaut E., Remon J.P. Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10. Eur J Pharm Biopharm 2005, 60(3):349-359.
68. Huyghebaert N., Vermeire A., Neirynck S., Steidler L., Remaut E., Remon J.P. Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing Lactococcus lactis. Eur J Pharm Biopharm 2005, 59(1):9-15.
69. Poelvoorde N., Huyghebaert N., Vervaet C., Remon J.P. Optimisation of an enteric coated, layered multi-particulate formulation for ileal delivery of viable recombinant Lactococcus lactis. Eur J Pharm Biopharm 2008, 69(3):969-976.
70. Termont S., Vandenbroucke K., Iserentant D., Neirynck S., Steidler L., Remaut E., et al. Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance. Appl Environ Microbiol 2006, 72(12):7694-7700.